News

TearSolutions, Inc. Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Lacripep™

CHARLOTTESVILLE, Va., (GLOBE NEWSWIRE) — TearSolutions, Inc. (“the Company”), a privately held developer of a replacement therapy for the treatment of Dry Eye Disease (DED) called Lacripep, today announced that in late 2021 it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Lacripep for the treatment of keratoconjunctivitis sicca, also known as DED, and is planning to begin one of two phase III trials.

Based on guidance the Company received, TearSolutions is preparing to conduct two phase III pivotal trials, one in a primary Sjögren’s Syndrome (pSS) patient population and the second in a potentially less severe general dry eye population. The first trial will be a multi-part Phase II/III trial where one study will be conducted in patients with DED associated with pSS to confirm results observed in the previously conducted Phase I/II trial and the other study will be in a general, potentially less severe, DED population. The second phase III trial is planned to be in a general DED population that will not exclude pSS patients. In addition, FDA provided guidance with regard to the study design for the first phase III, which has been incorporated into the trials’ preliminary design characteristics:

  • Number of patients: approximately 240
  • Patient populations: pSS associated DED and general DED
  • Primary endpoint: statistically significant improvement in both sign (inferior corneal fluorescein staining) and symptom (burning and stinging) as compared to baseline
  • Visits: Screening/Baseline, Week 2, Week 4, Week 6 and safety follow-up over the course of one year

The Company is currently planning the first phase III with targeted first enrollment in July 2022, for which the Company would expect top-line efficacy results from the general DED study in Q1 2023 and at the end of 2023 for the pSS DED study. The initiation and execution of the first phase III, beyond the start-up phase, is subject to additional funding or strategic partnering and may be further impacted by the COVID-19 pandemic.

“We thank FDA for the constructive comments, guidance and support related to the continued development of Lacripep,” commented Marc Odrich, Chief Medical Officer. “The feedback from FDA and our advisors, along with the learnings from our Phase I/II first-in-human trial has us convinced that we are on a path to bringing a novel and disruptive therapy to the market in Lacripep, which has the potential to address significant unmet needs for the millions of people suffering from Dry Eye Disease.”

Read more here.

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by